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Introduction
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine 
cancer of the skin with a quadrupled incidence in the past 15 years. 
 e mortality rate is 46%, exceeding that of melanoma, and there is 
presently no cure. Moreover, its incidence is approximately 11-fold 
in AIDS patients and 5-fold in organ transplant patients. In addition 
to skin cancers, patients with MCC have increased risk for multiple 
myeloma, non-Hodgkin’s lymphoma, and in particular chronic 
lymphocytic leukemia. Although chronic sun exposure, polyomavirus 
and immunosuppression have been implicated in the tumor 
development  [1-4], our understanding of the cellular and molecular 
mechanisms of MCC carcinogenesis and metastasis remains largely 
unknown.
Interrogation of MCC tumors of mutation of both tumor 
suppressor genes and oncogenes, such as p53, PTEN, Ras, B-RAF, c-kit, 
β-catenin, which are frequently involved in human cancers, have failed 
to reveal a signicant role in MCC  [5]. However, loss of the pRb1 gene 
region and amplication of the L-Myc gene region have been found 
at a signicant rate (26% and 31% of tumors, respectively) and have 
been postulated to have a functional role in tumor development  [6]. In 
search of receptor tyrosine kinase (RTK) involvement in MCC (and a 
rationale for the use of targeted therapies), studies have found variable 
expression of c-kit, VEGFs, PDGFα and PDGFβ in MCCs compared to 
normal skin  [7,8]. Moreover, study has shown MAP kinase pathway 
is silent (as demonstrated by lack of pathway activation and no ERK 
phosphorylation) in the majority of MCCs examined  [9]. Furthermore, 
a separate study using a MCC cell line demonstrates that inactivation 
of MAP kinase pathway is important in MCC carcinogenesis [10]. 
Additionally, one study using tissue microarray shows expressions 
of MMPs, VEGFs, P38, stromal NF-Kappa B and synaptophysin are 
associated with aggressive behavior [11]. 
Genomic studies such as chromosomal comparative genomic 
hybridization (CGH) have been employed to examine copy number 
alterations in MCCs. Chromosomes 1, 3q, 5p and 6 are frequently 
increased in copy number whereas chromosomes 3p, 4, 5q, 7, 10 and 
13 are frequently lost [12]. Additionally, transcriptome proling has 
identied a subgroup of MCCs with intratumoral CD8 positive T 
cell inltration thatis associated with better prognosis [13]. Although 
the causes of cancer lie in mutations or epigenetic changes at the 
chromosomal level, their molecular manifestation is correlated to the 
dysfunction of biochemical pathways at the protein level. In addition, the 
plasticity of mRNAs raises questions whether RNA expression changes 
are translated to those of proteins that are central to carcinogenesis. 
 erefore, dening the protein proles and dysregulation of their 
expression level in cancer is critical.
Global proteomic analysis has become a promising strategy to 
identify potential biomarkers in various cancer subtypes. However, 
one of the obstacles of human tissue research for proteomic study is the 
Abstract
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preferential use of snap frozen fresh tissues that are restricted in human 
skin biopsy samples.  e Liquid Tissue platform, a novel technology 
for protein extraction from formalin-xed, paran-embedded (FFPE) 
tissue blocks, permits facile global proteomic analysis of archival 
specimens by mass spectrometry to identify novel or critical proteins 
from human archival tissues. Moreover, no proteomic study has been 
performed in MCC and the proteins essential for the transformation of 
MCC have not been identied. 
In this study, we used a quantitative proteomic platform to 
assessprotein expression in FFPE MCC tumors. Because of the 
neuroendocrine nature of MCC, we chose another neuroendocrine 
tumor, carcinoid tumors of the lung, as the control. We identied 
signicantly over-expressed proteins in MCC. Interestingly, further 
pathway analysis of our protein data implicated the involvement of 
MAPK, PI3K/Akt/mTOR, wnt, and apoptosis signaling pathways. 
As shown previously mTOR pathway is activated in MCCs [14,15], 
therefore we selected this pathway for further investigation. Two 
molecules downstream of the mTOR pathway, lactate dehydrogenase 
B (LDHB) and heterogeneous ribonucleoprotein F (hnRNPF), were 
studied. We rst conrmed the expression of LDHB and hnRNPF in 
tissue microarray including 80 MCC samples and two primary human 
MCC cell lines established in the lab. Moreover, mTOR inhibition 
suppressed both LDHB and hnRNPF expression in MCC cells.  e 
results of the current study will provide insight into our understanding 
of MCC carcinogenesis and has translational potential for clinical 
practice by facilitating the identication of useful biomarkers for early 
diagnosis and prognosis as well as identifying novel therapeutic targets 
of MCC.
Materials and Methods
Sample selection and tissue microarray
In accordance with institutional approvals for human study 
protocol, a total of 10 MCCs and 5 carcinoid tumor of the lung 
formalin xed paran embedded (FFPE) tissue blocks were selected 
for proteomic study. Tissue microarray (TMA) included80 FFPE 
MCC tissue blocks and were prepared as previously described [15]. 
Briey, for each case a representative area from the tumor was carefully 
selected from a hematoxylin-eosin stained section of a MCC tissue 
block. Core cylinders (0.6 mm) were punched from each FFPE tumor 
and deposited into a recipient paran block using the MTA-I manual 
tissue arrayer (Beecher). Five-micrometer sections of the resulting 
TMA blocks were made and used for immunohistochemistry. 
Immunohistochemistry
Immunohistochemistry was performed on 5 µm sections of 
TMA slides.  e slides were deparanized and rehydrated in water. 
Antigen retrieval was performed by microwaving in 0.01 M sodium 
citrate for 20 min. Tissue peroxide activity was blocked with 1% 
hydrogen peroxide at room temperature (RT) for one hour followed 
by washing twice in PBS.  e sections were further blocked with 
normal goat serum at RT for one hour followed by incubation with 
LDHB (Lifespan Biosciences) and hnRNPF (Abcam) at 4°C overnight, 
respectively. Secondary goat anti-rabbit antibody (1:200) was applied 
to the slides for one hour at RT before developing in HRP detection 
system and freshly prepared diaminobenzidine as the chromogen 
(brown). Sections were counterstained with hematoxylin. Staining was 
manually scored. Immunostained slides were viewed on an Olympus 
BX51 Research System Microscope by 10x and 20x UPlanApo air 
objective lenses (Olympus America). Images were photographed using 
a high-resolution interline CCD camera (CoolSNAPcf, Photometrics), 
and acquired with automated microscopy acquisition soware 
(MetaMorph version 7.7, Molecular Devices).
Cell lines and reagents
In accordance with institutional approvals for human study 
protocol, we have established two primary human Merkel cell 
carcinoma cell lines (MCC-2 and MCC-3) from lymph node metastases 
of two patients [15]. Both cell lines were maintained in RPMI medium 
with 10% Fetal Bovine Serum (FBS), penicillin and streptomycin. Fresh 
medium was added every other day and cultures were split 1:2 weekly 
following complete removal of the medium. mTOR inhibitors Ku-
0063784 and PP242 were obtained from Sigma Aldrich.
Immunoblotting
Membranes were blotted with antibodies directed against (LDHB 
and hnRNPF). Bound antibodies were detected with horseradish 
peroxidase-linked antibody against mouse or antibody against rabbit 
(IgG; Amersham), followed by ECL detection (Amersherm).
Gene expression analysis
RNAs were isolated from MCC fresh tissues and control carcinoid 
tumors of the lung with RNeasy kit (Qiagen). cDNA was generated 
from mRNA using a Reverse Transcription Kit (Applied Biosystems). 
SYBR Green-based quantitative reverse transcription-PCR (qRT-PCR) 
was performed with a StepOnePlus Real-Time PCR System (Applied 
Biosystems). Triplicate runs of each sample were normalized to MRPS2 
mRNA to determine relative expression. 
Quantitative proteomics
A single 10 µm tissue section was made and mounted on Director 
slide (Expression Pathology, Gaithersburg, MD), and heated for 1 
hour at 60°C. Paran was removed with xylene followed by tissue 
rehydration through a series of graded ethanol solutions and distilled 
water. Approximately 30,000 tumor cells were procured by needle 
microdissection. 
 e Liquid Tissue MS Protein Prep Kit (Expression Pathology) 
was used to reverse cross-linking and the extracted proteins were 
analyzed by Coomassie/sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Each SDS-PAGE gel lane was cut into 3 
mm slices and subjected to in-gel trypsin digestion as follows. Protein-
containing gel slices were destained in 50% methanol (Fisher), 100 mM 
ammonium bicarbonate (Sigma-Aldrich), followed by reduction in 
10 mM Tris [2-carboxyethyl]phosphine (Pierce) and alkylation in 50 
mM iodoacetamide (Sigma-Aldrich). Gel slices were then dehydrated 
in acetonitrile (Fisher), followed by addition of 100 ng porcine trypsin 
(Promega) in 100 mM ammonium bicarbonate (Sigma-Aldrich) 
and incubation at 37°C for 12-16 hours. Peptide products were then 
acidied in 0.1% formic acid (Fluka). Tryptic peptides were separated 
by reverse phase Jupiter Proteo resin (Phenomenex) on a 100×0.1 mm 
column using a nanoLC 2D system (Eksigent). Peptides were eluted 
using a 30 min gradient from 98:2 to 40:60 buer A:B ratio. [Buer 
A=0.1% formic acid, 0.05% acetonitrile; buer B=0.1% formic acid, 
75% acetonitrile.] Eluted peptides were ionized by electrospray (2.0 
kV) followed by MS/MS analysis using collision induced dissociation 
on an LTQ XL mass spectrometer ( ermo). MS data were acquired 
over a range of 375 to 1500 m/z. MS/MS data were acquired for the top 
7 peaks from each MS scan. Proteins were identied by database search 
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using Mascot (Matrix Science).Tandem mass spectrometric data was 
searched with an in-house version of Mascot against the UniprotKB/
SwissProt Homo sapiens protein database for protein identication. 
In order to quantify the relative protein level in these samples, we 
used a mass spectrometric technique called spectral counting using 
parameters as detailed by Byrum et al. [16]. A spectral count is the 
number of tandem mass spectra assigned to a given protein and reects 
the abundance of the protein. We then calculated a normalized spectral 
abundance factor (NASF), which reects the amount of a given protein 
relative to the total proteins identied in the gel lane [17,18].  e NASF 













 e variables are dened as follows: k is a given protein, SpC are the 
spectral counts, L is the length of the protein, and N is the sum of all 
proteins identied in the gel lane. For a given protein, this reveals what 
fraction of the total proteins identied in the gel lane is the particular 
protein.  e data distribution of the normalized spectral counts showed 
a bimodal distribution and therefore, the Wilcoxon rank sum test with 
the t-approximation was used to identify signicantly dierentiating 
proteins between the two groups.  e enrichment level for each protein 
was identied by calculating the fold change (CK/Lung) using the 
average ln (NSAF) values for each protein. Fold change was calculated 
by taking the anti-log of (ln(NSAF)avg CK–ln(NSAF)avg Lung). Proteins 
with a p-value<0.05 and a FC>1.5 were considered signicant. 
 e most important signaling pathways were identied using the 
Database for Annotation, Visualization and Integrated Discovery 
(DAVID) v6.7 [19]. Signicantly dierentiating proteins, not identied 
in signaling pathways by DAVID, were searched in the literature using 
a web-based search tool, PubTator, for involvement in known pathways 
using the protein’s gene symbol plus the keyword “pathway” [20,21]. 
Results
Distinct protein expression proles in Merkel cell carcinoma
 e proteome from 10 metastatic MCC tumors and 5 carcinoid 
tumor of the lung were measured in this study. As shown in Figure 1, 
each protein sample was resolved by Coomassie/SDS-PAGE followed 
by in-gel trypsin digestion and LC-MS/MS. A total of 1356 proteins 
were identied for all samples at a 1% false discovery rate using a decoy 
database. To determine whether a protein was dierentially expressed 
between MCC and the carcinoid tumors of the lung, a label-free 
approach based on spectral counting was used  [18,22-24].  e relative 
abundance of each protein was normalized using the normalized 
spectral abundance factor (NSAF) and the frequency distribution of 
ln(NSAF) values showed a bimodal distribution.  ere were a total 
of 432 proteins identied with a fold change>1.5 in MCCs compared 
to the carcinoid tumor of lung. A Wilcoxon rank sum test with 
t-approximation identied 375 signicantly dierentiating proteins 
between MCCs and carcinoid tumor of the lung with a p-value<0.05. 
A heat map was generated using Hierarchical Clustering Explorer 
(HCE version 3.0) with all 375 signicant proteins, the average linkage 
method, and Euclidean distance metric.  e MCC and carcinoid tumor 
of the lung patient samples were clearly separated into two separate 
clusters based on these signicantly dierentiating proteins. Up- or 
down-regulated proteins in MCCs are indicated in red and green, 
respectively (Figure 2). 
Pathway analysis using DAVID uncovered several signaling 
pathways that are potentially important for MCC pathogenesis (Table 
1). Proteins identied are also known to play a role in multiple diseases 
such as Parkinson’s disease, Huntingtons disease, systemic lupus 
erythematosus, and areassociated with normal metabolic activities 
such as the citrate cycle, glycolysis/gluconeogenesis, and metabolism 
of amino acids. Of particular interest are proteins involved in focal 
adhesion, epithelial cell signaling, and the spliceosome. A manual 
literature search using the signicantly dierentiatingproteins in 
PubTatorhas revealed proteins involved in MAPK, PI3K/Akt/mTOR, 
wnt, and apoptosis signaling pathways (Table 2). Interestingly, we have 
uncovered several proteins involved in the MAPK pathway, which 
has previously been indicated as silent in MCCs [10].  e PI3K/AKT/
mTOR signaling cascade is commonly dysregulated in human cancers 
[25-27]. Moreover, we have found mTOR activation is common 
in MCCs [15].  erefore, we have selected two proteins, LDHB and 
hnRNPF, which are found to be signicantly up-regulated in MCCs 
and are downstream eectors of mTOR pathways, for further study 
and validation.
Expressions of LDHB and hnRNP are up-regulatedin fresh 
tumor tissues and primary human MCC cell lines at the 
mRNA level
 e mammalian target of rapamycin (mTOR) pathway is a master 
regulator of protein synthesis and frequently activated in human 
cancers [28]. mTOR resides in two complexes, mTOR complex1 
Figure 1: Representative gel lanes for quantitative mass spectrometric 
analysis of MCC and carcinoid tumor of the lung from formalin-¿xed 
paraf¿n-embedded (FFPE) tissues. Proteins were extracted from 10 MCC 
FFPE tissues and 5 carcinoid tumors of the lung FFPE tissues. The samples 
were equally loaded and resolved by sodium dodecyl sulfate polyacrylamid 
gel electrophoresis (SDS-PAGE)/Coomassie. Each gel lane was sliced into 23 
bands, subjected to trypsin digestion and peptides were analyzed by liquid 
chromatography-mass spectrometry (LC-MS)/MS with a Thermo LTQ-XL mass 
spectrometer. Proteins were identi¿ed by a Mascot database search (95% 
con¿dence threshold). One gel lane from each group is shown.
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(mTORC1) and mTOR complex (mTORC2), which execute distinct 
cellular tasks. Rapamycin and its analogues are allosteric inhibitors 
via mTORC1 inhibition. Underscored by the clinical inecacy of 
allosteric inhibitors, more potent inhibitors of the active site of 
mTOR kinase, such as PP242 and Ku-0063794, have been developed. 
 e major regulators of protein synthesis downstream of mTOR are 
eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 
(4E-BP1) and S6 kinase (S6K). Similar to 4E-BP1, dysregulation of S6K 
signaling has been linked to human pathologies, including cancer and 
diabetes.  ere are two isoforms, S6K1 and S6K2, which are found to 
be up-regulated at both the RNA and protein levels in several types of 
human cancers. In contrast to S6K1, the S6K2 is specially associated 
with a number of RNA-binding proteins, including heterogeneous 
ribonucleoproteins (hnRNPs). Moreover, hnRNPF has been shown to 
regulate cell proliferation via S6K2 in breast cancer cell lines [29]. 
In tumor cells, glucose is preferentially converted into lactic acid 
through aerobic glycolysis, which is known as the “Warburg eect”. 
LDH is the key glycolytic enzyme catalyzing the formation of lactic acid 
from pyruvate, is oen activated in cancers [30]. LDHB is critical for 
hyperactive mTOR mediated tumorigenesis. 
Taking advantage of two primary human MCC cells lines 
established in our laboratory as well as fresh MCC tumor samples, we 
measured the expression of LDHB and hnRNPF at the mRNA level. 
mRNAs were extracted from fresh tumors, MCC-2 and MCC-3 cell 
lines followed by qPCR. cDNA from a fresh carcinoid tumor of the 
lung was used as a control. Compared to the carcinoid tumor of the 
lung, signicantly increased expression of LDHB and hnRNPF was 
found in 16/16 and 11/16 fresh MCC tumors, respectively (Figure 3). 
Similarly, both MCC-2 and MCC-3 cell lines demonstrated increased 
expression of both mRNAs.  erefore, we have demonstrated over-
expression of LDHB and hnRNPF at the mRNA level in MCCs, which 
conrms our proteomic results.
LDHB and hnRNPF are over-expressed in human MCC tissue 
microarray samples
To further conrm our observations, we examined 80 MCC 
tumor samples using TMA. As shown in Figure 4, over-expression as 
indicated by positive nuclear staining of hnRNPF (brown) and positive 
cytoplasmic staining of LDHB (brown), respectively. Over-expression 
of LDHB and hnRNPF was detected in the majority of MCCs. Seventy-
four out of eighty (92.5%) and seventy-eight out of eighty (97.5%) 
MCC samples were positive for LDHB and hnRNPF, respectively. us, 
we have shown up-regulation of LDHB and hnRNPF in MCCs at the 
protein level, which again conrms our proteomic studies.
mTOR inhibitions suppresses LDHB and hnRNPF 
expressions in both MCC-2 and MCC-3 cells
To evaluate whether LDHB and hnRNPF are downstream eectors 
of the mTOR pathway, MCC-2 and MCC-3 cellswere treated with 
the active site ATP mTOR inhibitors Ku-0063784 and PP242 for 24 
hours, respectively. Cell lysates were subjected to LDHB and hnRNPF 
immunoblotting. mRNAs were extracted from MCC-2 and MCC-3 
cells treated with mTOR inhibitors followed by qPCR analysis of LDHB 
and hnRNPF. Consistent with previous ndings in other types of 
human cancer [29,30], reduced LDHB and hnRNPF expressions were 
observedboth at the mRNA and protein levels in MCC-2 and MCC-3 
cells following mTOR pathway inhibition, indicating that LDHB and 
hnRNPF are downstream eectors of mTOR pathway (Figure 5). 
Figure 2: Hierarchical clustered heat map of the 375 signi¿cant proteins 
differentially expressed between MCC and carcinoid tumors of the lung 
as determined by Wilcoxon rank sum test (p < 0.05). LDHB and hnRNPF 
proteins were upregulated in MCC tumors compared to carcinoid tumors of the 
lung and were selected for further validation.  
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Table 1: Signaling pathways identi¿ed by DAVID. The list of signi¿cantly differentiating proteins between MCC and carcinoid tumors of the lung was imported into the 
DAVID functional annotation web-tool.  The proteins identi¿ed in signaling pathways from the KEGG database are listed.
Pathway Count P-value Proteins Fold Enrichment Bonferroni Benjamini FDR
Oxidative phosphorylation 24 8.09E-11
UQCRC1, ATP6AP1, ATP6V1G1, COX5A, 
UQCRFS1, COX5B, UQCRQ, UQCRFSL1, 
NDUFS7, NDUFS6, NDUFS4, ATP5L, 
ATP6V0D1, ATP5I, NDUFS1, NDUFA5, 
NDUFA2, ATP5F1, ATP6V1H, ATP6V1F, 
COX6C, NDUFV1, ATP6V1E1, ATP6V0A1, 
UQCRB
5.18657 1.00E-08 1.00E-08 9.34E-08
Parkinson’s disease 18 2.00E-06
NDUFA5, NDUFA2, UQCRC1, SLC25A4, 
ATP5F1, COX5A, VDAC2, UQCRFS1, 
UQCRQ, COX5B, UQCRFSL1, COX6C, 
VDAC1, NDUFS7, NDUFS6, NDUFS4, 
NDUFV1, NDUFS1, UQCRB
3.950708 2.48E-04 1.24E-04 0.00231
Huntington’s disease 19 5.51E-05
NDUFA5, NDUFA2, UQCRC1, SLC25A4, 
ATP5F1, COX5A, VDAC2, UQCRFS1, 
UQCRQ, COX5B, UQCRFSL1, COX6C, 
VDAC1, DCTN2, NDUFS7, NDUFS6, 
NDUFS4, NDUFV1, NDUFS1, UQCRB
2.96547 0.006812 0.002276 0.063633
Systemic lupus erythematosus 13 1.68E-04
HLA-DRB1, ACTN4, C4A, SNRPD3, ACTN1, 
HIST1H2BO, TROVE2, HIST1H2BL, 
HIST1H3A, H2AFY2, SNRPB, H2AFY, 
H3F3A
3.689101 0.020611 0.005193 0.193756
Vibrio cholerae infection 9 6.99E-04
ACTG1, ACTB, ATP6AP1, ATP6V1E1, 
ATP6V1H, ATP6V0A1, ATP6V1G1, 
ATP6V0D1, ATP6V1F
4.515095 0.083065 0.017194 0.804307
Spliceosome 13 0.001537
SNRPA1, SNRPD3, SNRPD2, HNRNPA1, 
NAA38, SF3B3, HNRNPU, RBM8A, PCBP1, 
SNRPB, MAGOHB, SNRNP70, SNRPE
2.898579 0.173673 0.031294 1.760801
Cardiac muscle contraction 10 0.001584
ATP1B1, ACTC1, UQCRC1, ATP1A1, 
UQCRFS1, COX5A, UQCRQ, COX5B, 
UQCRFSL1, UQCRB, COX6C
3.601785 0.178439 0.027688 1.81371
Alzheimer’s disease 15 0.001737
NDUFA5, NDUFA2, UQCRC1, ATP5F1, 
COX5A, UQCRFS1, COX5B, UQCRQ, 
UQCRFSL1, COX6C, NDUFS7, NDUFS6, 
NDUFS4, NDUFV1, NDUFS1, UQCRB
2.58533 0.193896 0.026583 1.987221
Figure 3: Expression of LDHB and hnRNPF in fresh MCC tumor tissues and two primary human MCC cell lines. cDNAs were extracted from 16 fresh MCC 
tumors and 2 primary human MCC cell lines and qRT-PCR analysis of LDHB and hnRNPF mRNA expression was performed. cDNA from a fresh carcinoid tumor 
of the lung was used as a control. Triplicate runs of each sample were normalized to MRPS2 mRNA to determine relative expression (means ± SEM), (**P < 0.01, 
***P< 0.001).
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Serpin H1 SERPINH1 20188343
Guanine nucleotide-binding protein 
subunit beta-2-like 1 GNB2L1 22240482
Collagen alpha-2(I) chain COL1A2 22131293
UDP-glucose 6-dehydrogenase UGDH 14505572
Metalloproteinase inhibitor 1 TIMP1 23555182
Carboxypeptidase E OS CPE 22824791
Hepatoma-derived growth factor-related 
protein 3 HDGFRP3 22490522
Ras-related protein Rab- RAB7A 19372461
ATP synthase subunit e, mitochondrial 
OS ATP5I 11939412
Chromogranin-A OS CHGA 10197763
Galectin-3-binding protein LGALS3BP 22389450
Peroxiredoxin-6 PRDX6 21346153
Stress-70 protein, mitochondrial HSPA9 12646231
Annexin A2 OS ANXA2 22040021
Peroxiredoxin-1 PRDX1 23602274
RasGAP-like with IQ motifs IQGAP1 23603816
Tripeptidyl-peptidase 1 TPP1 22101936
Filamin-A FLNA 22203038
Apoptosis
FACT complex subunit SSRP1 SSRP1 16498457
Apoptosis-inducing factor 1, 
mitochondrial OS AIFM1 16636662
Cytochrome c oxidase subunit 6C COX6C 22860893
Diablo homolog, mitochondrial DIABLO 10972280
Eukaryotic translation initiation factor 3 
subunit B EIF3B 22234522
Glutaredoxin-1 GLRX 17185628
Glutathione peroxidase 3 GPX3 22461624
Heterogeneous nuclear 
ribonucleoprotein U HNRNPU 20101230
Mitochondrial carrier homolog 2 MTCH2 15899861
Pro¿lin-1 PFN1 23331014
Rho GDP-dissociation inhibitor 1 ARHGDIA 19077262
Sorcin SRI 22052463
Very long chain acyl-CoA 
dehydrogenase, mitochondrial ACADVL 9680378
Polyadenylate-binding protein 2 PABPN1 22519734
Galectin-7 LGALS7 21289092
DNA replication licensing factor MCM3 MCM3 10495426
Annexin A2 OS ANXA2 22040021
Protein Name Gene symbol PMID
PI3K/Akt/mTOR Pathway




Proliferating cell nuclear antigen PCNA 23298485
Filamin-A FLNA 22203038
Aldo-keto reductase family 1 member 
C3 OS AKR1C3 18508192
ATP-citrate synthase OS ACLY 18922930
Stathmin STMN1 21683992
Serum amyloid P-component APCS 23182717
UDP-glucose 6-dehydrogenase UGDH 14505572
Keratin, type II cytoskeletal 8 KRT8 23449973
Metalloproteinase inhibitor 1 TIMP1 23555182
Collagen alpha-1(VI) chain COL6A1 11279127
Collagen alpha-3(VI) chain COL6A3 11279127
Heterogeneous nuclear 
ribonucleoprotein F HNRNPF     21157483
L-lactate dehydrogenase B chain LDHB 21199794
Poly [ADP-ribose] polymerase 1 PARP1 17525332
Small nuclear ribonucleoprotein E SNRPE 23358685
Guanine nucleotide-binding protein 
subunit beta-2-like 1 GNB2L1 22240482
Wnt Pathway
Carboxypeptidase E OS CPE 22824791
ATP-dependent RNA helicase DDX3X DDX3X 23413191
High mobility group protein B2* HMGB2 19805379
Guanine nucleotide-binding protein 
subunit beta-2-like 1 GNB2L1 22240482
Glutathione S-transferase Mu 3 GSTM3 20118494
Methyl-CpG-binding protein 2 MECP2 23200852
Moesin MSN 23221384
Ras GTPase-activating protein-binding 
protein 1 G3BP1 21652632
Annexin A1 OS ANXA1 21383699
Table 2: Proteins identi¿ed in PI3K/Akt/mTOR, p38 MAPK, Apoptosis, and 
wnt signaling pathways. The protein name, gene symbol, accession number, and 
PubMed identi¿er (PMID) for the journal linking the protein to a particular signaling 
pathway are listed for each protein.
Discussion
A hallmark of human cancer is heterogeneity. At the genetic level, 
it reects the complex series of changes resulting in the activation of 
oncogenes coupled with inactivation of tumor suppressor genes. At 
the patient level, it manifests by disease outcome, response to therapy 
and ability to metastasize. At the pathological level, it is observed 
where certain histological features are associated with more aggressive 
cancers. An ability to model this complexity is crucial to identify 
therapeutic targets for cancers evading therapy. However, targeted 
therapy at the gene level remains a challenge as there is a distinction 
between driver mutations that can propel the development of cancer 
and driver mutations on which the cancer cell continually depends. 
Interrogation of tumors at the genomic and transcriptomic level may 
therefore not precisely present the complexity of the tumor itself or 
its biologic environment, including uctuating in clonal variation, 
changes in in gene expression and host response, and signaling events 
that lead to changes at the protein level. Because many drugs act on 
protein eectors, in combination with genomic and transcriptomic 
proling, proteomic proling oers the promise of additional insights 
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Figure 4: hnRNPF and LDHB expression in MCC tissue microarray 
samples. (A-D) Representative negative and positive immunohistochemical 
staining of hnRNPF (brown nuclear staining) and percentages of negative 
samples, and samples with weak, moderate and strong positives.  (E-H) 
Representative negative and positive immunohistochemical staining of LDHB 
(brown cytoplasmic staining) and percentages of negative samples, and 
samples with weak, moderate and strong positives.
into cancer status and may be a better approach to identify therapeutic 
targets. 
Merkel cell carcinoma is a neuroendocrine skin tumor with 
aggressive behavior and poor prognosis. Fiy percent of patients are 
metastatic upon diagnosis. Despite standard treatment that is surgery 
followed by radiation therapy, one third of patients eventuate distant 
metastasis. Evidence-based eective chemotherapy for metastatic 
disease has not yet developed. We have taken the approach to 
investigate metastatic tissue, with the rationale that the tumor cells 
present in lymph node are molecularly programmed to “escape” 
surveillance mechanisms and metastasize – the ultimate behavior that 
drives disease progression. In this study, taking advantage of the liquid 
platform technique using archival tissues to identify molecules that are 
integral to specic signaling pathways known to be important in tumor 
biology. We have identied increased expression of members of the 
RTK/PI3K/Akt/mTOR, wnt and MAPK pathways, which we propose 
are important in MCC pathogenesis. In fact, we have conrmed the 
overexpression of LDHB and hnRNPF, two downstream mTOR 
eectors in MCCs by qPCR and immunoblotting, supporting the 
involvement of this pathway in MCC tumorogenesis.
Increased expression of LDHB in MCCs suggests increased tumor 
metabolism depending on glycolysis in energy demand and further 
implies the idea that MCCs are sensitive to perturbation in the end 
stage of glycolysis-lactate production, and thus open a therapeutic 
window in the clinics. Moreover, increased expression of hnRNPF is 
indicative of additional molecules along mTOR pathway other than 
4E-BP1 and S6K1 involved in MCC pathogenesis. Aberrant RTK/
PI3K/Akt/mTOR pathway has a key role in human cancer initiation, 
progression, invasion, metastasis and resistance to therapy. Our current 
study supports the ndings of two separate independent studies, which 
has revealed a dysregulated RTK/PI3K/Akt/mTOR pathway in MCC 
[25,26]. Cumulatively, these ndings suggest that inhibitors of this 
pathway hold treatment promise in these tumors, either as initial single 
agents, or in combination with standard cytotoxic chemotherapy and 
radiotherapy.
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Figure 5: mTOR inhibition suppresses LDHB and hnRNPF expression in 
both MCC-2 and MCC-3 cells. (A) Suppressed LDHB and hnRNPF mRNA 
expression in MCC-2 and MCC-3 cells. MCC-2 and MCC-3 cells were treated 
with DMSO, Ku-0063794 (5μM) and PP242 (2.5μM) for 24 hours, respectively. 
cDNAs were extracted and expression of hnRNPF and LDHB was analyzied 
by qPCR. Triplicate runs of each sample were normalized to MRPS2 mRNA 
to determine relative expression (means ± SEM), (*P < 0.05, ***P< 0.001). 
(B) Suppressed mTOR pathway, LDHB and hnRNPF protein expressions in 
MCC-2 and MCC-3 cells by immunoblottings.  MCC-2 and MCC-3 cells were 
treated with DMSO, Ku-0063794 (5μM) and PP242 (2.5μM) for 24 hours, 
respectively. Lysates were prepared and subjected to immunoblotting analysis 
with indicated antibodies. β-actin served as proper loading control.
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